1477 Results

People

  1. Motzer
    Motzer
  2. Hudis
    Hudis
  3. Aghajanian
    Aghajanian
  4. O'Reilly
    O'Reilly
  5. Kris
    Kris
  6. Scher
    Scher
  7. Panageas
    Panageas
  8. Saltz
    Saltz
  9. Schwartz
    Schwartz
  10. Kelsen
    Kelsen

Groups

  1. Department of Medicine (1039)
  2. Solid Tumor Oncology Division (784)
  3. Hematologic Malignancies, Division of (287)
  4. Survivorship Research (234)
  5. Center for Hematologic Malignancies (216)
  6. Genitourinary Oncology Service (208)
  7. Epidemiology and Biostatistics (194)
  8. Biostatistics Service (169)
  9. Gastrointestinal Oncology Service (160)
  10. Population Sciences Research Program (158)
  1. "fatigue"
Formats
  1. Journal Article (1402)
  2. Review (38)
  3. Research Letter (13)
  4. Editorial (10)
  5. Conference Paper (5)
  6. Guidelines (4)
  7. Correspondence (3)
  8. Book Section (2)
Groups
  1. Department of Medicine (1039)
  2. Solid Tumor Oncology Division (784)
  3. Hematologic Malignancies, Division of (287)
  4. Survivorship Research (234)
  5. Center for Hematologic Malignancies (216)
  6. Genitourinary Oncology Service (208)

More Groups

People
  1. Robert Motzer (85)
  2. Clifford Hudis (49)
  3. Carol Aghajanian (46)
  4. Eileen O'Reilly (46)
  5. Howard Scher (44)
  6. Mark Kris (44)

More People

Years
  1. 2025 (60)
  2. 2024 (132)
  3. 2023 (89)
  4. 2022 (46)
  5. 2021 (33)
  6. 2020 (85)

More Years

Publications
  1. Journal of Clinical Oncology (108)
  2. Clinical Cancer Research (82)
  3. Cancer (63)
  4. Lancet Oncology (50)
  5. Gynecologic Oncology (41)
  6. Annals of Oncology (37)

More Publications

Publishers
  1. Elsevier Inc. (244)
  2. Springer (133)
  3. American Society of Clinical Oncology (114)
  4. Elsevier Science, Inc. (108)
  5. Oxford University Press (101)
  6. American Association for Cancer Research (89)

More Publishers

Results (1477)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Daratumumab plus lenalidomide/dexamethasone in untreated multiple myeloma: Analysis of key subgroups of the MAIA study
    Journal Article

    Moreau, P.; Facon, T.; Usmani, S. Z.; Bahlis, N.; Raje, N.; Plesner, T.; Orlowski, R. Z.; Basu, S.; Nahi, H.; Hulin, C.; more...
    Leukemia (2025)

    Fulltext@MSK | Save
  • Top ten tips palliative care clinicians should know about diagnosing, categorizing, and addressing fatigue
    Editorial

    Robbins-Welty, G. A.; Chammas, D.; Silverman, E. J.; Lowry, M. F.; Hale, E.; Martinez, C.; Nakatani, M. M.; Shalev, D.; Noufi, P.; Riordan, P. A.; more...
    Journal of Palliative Medicine (2025)

    Fulltext@MSK | Save
  • Selective intra-arterial mitomycin-C infusions for treatment-refractory colorectal liver metastases
    Journal Article

    Sotirchos, V. S.; Silk, M. T.; Camacho, J. C.; Schatoff, E. M.; Kunin, H. S.; Alexander, E. S.; Zhao, K.; Connell, L. C.; Sofocleous, C. T.; Kemeny, N. E.
    Journal of Gastrointestinal Oncology (2025)

    Fulltext@MSK | Save
  • A phase I, first-in-human trial of KO-947, an ERK1/2 inhibitor, in patients with advanced solid tumors
    Journal Article

    Schram, A. M.; Boni, V.; Adjei, A. A.; Olszanski, A. J.; Vieito, M.; Francis, J. H.; Kurman, M.; Ahsan, J. M.; Tomkinson, B.; Garralda, E.
    ESMO Open (2025)

    Fulltext@MSK | Save
  • Exploring the landscape of integrative medicine in pediatric oncology: Characterization of an outpatient consultative service
    Journal Article

    Wu, H. W. V.; Dominguez Garcia, D.; Glade Bender, J. L.; Mao, J. J.; Raghunathan, N. J.
    Children (2025)

    Fulltext@MSK | Save
  • A phase 1 study of the combination of BH3-mimetic, navitoclax, and mTORC1/2 inhibitor, vistusertib, in patients with advanced solid tumors
    Journal Article

    Scott, S. C.; Farago, A.; Lai, W. V.; Zahurak, M.; Rudek, M. A.; Murray, J.; Carducci, M. A.; Uziel, T.; Takebe, N.; Gore, S. D.; more...
    Cancer Chemotherapy and Pharmacology (2025)

    Fulltext@MSK | Save
  • Local therapy for isolated central nervous system progression among patients receiving antibody-drug conjugate therapy
    Research Letter

    Lebow, E. S.; Eichholz, J.; Zhang, Z.; Toumbacaris, N.; Imber, B.; Chen, L.; LaPlant, Q.; Yamada, J.; Pike, L. R. G.; Modi, S.; more...
    Advances in Radiation Oncology (2025)

    Fulltext@MSK | Save
  • Neurotoxicity and rare adverse events in BCMA-Directed CAR t cell therapy: A comprehensive analysis of real-world FAERS data
    Journal Article

    Ellithi, M.; Elsallab, M.; Lunning, M. A.; Holstein, S. A.; Sharma, S.; Trinh, J. Q.; Ma, J.; Maus, M. V.; Frigault, M. J.; D'Angelo, C. R.
    Transplantation and Cellular Therapy (2025)

    Fulltext@MSK | Save
  • SWOG S1815: A phase III randomized trial of gemcitabine, cisplatin, and nab-paclitaxel versus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancers
    Journal Article

    Shroff, R. T.; King, G.; Colby, S.; Scott, A. J.; Borad, M. J.; Goff, L.; Matin, K.; Mahipal, A.; Kalyan, A.; Javle, M. M.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Clinical outcomes, patterns of failure, and salvage therapies of a large modern cohort of patients with anal squamous cell carcinoma treated with definitive-intent intensity-modulated radiation therapy
    Journal Article

    Roth O'Brien, D. A.; Hristidis, V. C.; Chakrani, Z.; McCann, P.; Damato, A.; Williams, V.; Cote, N.; Reyngold, M.; Rosen, R.; Connell, L.; more...
    International Journal of Radiation Oncology, Biology, Physics (2025)

    Fulltext@MSK | Save